Glycoconjugate vaccines

The Magnitude of the Antibody and Memory B Cell Responses during Priming with a Protein-Polysaccharide Conjugate Vaccine in Human Infants Is Associated with the Persistence of Antibody and the Intensity of Booster Response

(2014) G. B. Rohner et al.   JOURNAL OF IMMUNOLOGY

Prevalence of Serum Bactericidal Antibody to Serogroup C Neisseria meningitidis in England a Decade after Vaccine Introduction

(2012) David A. Ishola et al.   Clinical and Vaccine Immunology

13-valent Pneumococcal Conjugate Vaccine Given With Meningococcal C–Tetanus Toxoid Conjugate and Other Routine Pediatric Vaccinations

(2012) Federico Martinón-Torres et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity of a Single Dose of Meningococcal Group C Conjugate Vaccine Given at 3 Months of Age to Healthy Infants in the United Kingdom

(2012) Helen Findlow et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity

(2012) R. Malley et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens

(2012) Davide Serruto et al.   VACCINE

Characterization of size, structure and purity of serogroup X Neisseria meningitidis polysaccharide, and development of an assay for quantification of human antibodies

(2012) Ouli Xie et al.   VACCINE

Effectively introducing a new meningococcal A conjugate vaccine in Africa: The Burkina Faso experience

(2012) Mamoudou H. Djingarey et al.   VACCINE

Increase of meningococcal serogroup Y cases in Europe: A reason for concern?

(2012) Michael Bröker et al.   Human Vaccines & Immunotherapeutics

Meningococcal Group C and W135 Immunological Hyporesponsiveness in African Toddlers

(2011) Helen Findlow et al.   Clinical and Vaccine Immunology

Geographic Variation in Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccine Introduction in the United States

(2011) J. B. Rosen et al.   CLINICAL INFECTIOUS DISEASES

The design of semi-synthetic and synthetic glycoconjugate vaccines

(2011) Paolo Costantino et al.   Expert Opinion on Drug Discovery

Review on the immunogenicity and safety of PCV-13 in infants and toddlers

(2011) Marta C Nunes et al.   Expert Review of Vaccines

Hyporesponsiveness Following Booster Immunization With Bacterial Polysaccharides Is Caused by Apoptosis of Memory B Cells

(2011) Siggeir F. Brynjolfsson et al.   JOURNAL OF INFECTIOUS DISEASES

Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study

(2011) Elizabeth Miller et al.   LANCET INFECTIOUS DISEASES

Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans

(2011) Samba O. Sow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunogenicity of 10-Valent Pneumococcal Nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine When Administered as Catch-up Vaccination to Children 7 Months to 5 Years of Age

(2011) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity, Safety, and Reactogenicity of the 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine and DTPa-IPV-Hib When Coadministered as a 3-dose Primary Vaccination Schedule in the Netherlands

(2011) Menno R. van den Bergh et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

The Impact of the Heptavalent Pneumococcal Conjugate Vaccine on the Epidemiology of Acute Otitis Media Complicated by Otorrhea

(2011) Kostantinos Stamboulidis et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity of a Single Dose of Tetravalent Meningococcal Serogroups A, C, W-135, and Y Conjugate Vaccine Administered to 2- to 10-year-olds Is Noninferior to a Licensed-ACWY Polysaccharide Vaccine With an Acceptable Safety Profile

(2011) Ziad A. Memish et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults 10 to 25 Years of Age

(2011) Roger Baxter et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Emergence of Epidemic Neisseria meningitidis Serogroup X Meningitis in Togo and Burkina Faso

(2011) Isabelle Delrieu et al.   PLoS One

Safety, Immunogenicity and Dose Ranging of a New Vi-CRM197 Conjugate Vaccine against Typhoid Fever: Randomized Clinical Testing in Healthy Adults

(2011) Pierre van Damme et al.   PLoS One

Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine

(2011) Francisco Gimenez-Sanchez et al.   VACCINE

An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12–23-month-old children

(2011) Markus Knuf et al.   VACCINE

Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children

(2011) Anna S. Tocheva et al.   VACCINE

The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A

(2011) David Cooper et al.   VACCINE

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants

(2011) E. Grimprel et al.   VACCINE

Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

(2011) Elizabeth Miller et al.   VACCINE

A New Pneumococcal Serotype, 11E, Has a Variably InactivatedwcjEGene

(2010) Juan J. Calix et al.   JOURNAL OF INFECTIOUS DISEASES

Production of glycoprotein vaccines in Escherichia coli

(2010) Julian Ihssen et al.   Microbial Cell Factories

Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age

(2010) Matthew D. Snape et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

National Hospitalization Trends for Pediatric Pneumonia and Associated Complications

(2010) G. E. Lee et al.   PEDIATRICS

Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers

(2010) S. H. Yeh et al.   PEDIATRICS

Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008

(2010) E. Koshy et al.   THORAX

Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany

(2010) Dorothee M. Kieninger et al.   VACCINE

Systematic Evaluation of Serotypes Causing Invasive Pneumococcal Disease among Children Under Five: The Pneumococcal Global Serotype Project

(2010) Hope L. Johnson et al.   PLOS MEDICINE

Kinetics of Antibody Persistence following Administration of a Combination Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine in Healthy Infants in the United Kingdom Primed with a Monovalent Meningococcal Serogroup C Vaccine

(2009) R. Borrow et al.   Clinical and Vaccine Immunology

Quadrivalent Meningococcal Vaccination of Adults: Phase III Comparison of an Investigational Conjugate Vaccine, MenACWY-CRM, with the Licensed Vaccine, Menactra

(2009) K. S. Reisinger et al.   Clinical and Vaccine Immunology

Phase III Comparison of an Investigational Quadrivalent Meningococcal Conjugate Vaccine with the Licensed Meningococcal ACWY Conjugate Vaccine in Adolescents

(2009) Lisa A. Jackson et al.   CLINICAL INFECTIOUS DISEASES

The Immunogenicity of 7‐Valent Pneumococcal Conjugate Vaccine versus 23‐Valent Polysaccharide Vaccine in Adults Aged 50–80 Years

(2009) David Goldblatt et al.   CLINICAL INFECTIOUS DISEASES

10-valent pneumococcal nontypeableHaemophilus influenzaePD conjugate vaccine: Synflorix™

(2009) Roman Prymula et al.   Expert Review of Vaccines

Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine

(2009) Tamara Pilishvili et al.   JOURNAL OF INFECTIOUS DISEASES

Safety and Immunogenicity of a Tetravalent Polysaccharide Vaccine Against Meningococcal Disease

(2009) Pei-Lan Shao et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

(2009) Katherine L O'Brien et al.   LANCET

Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates

(2009) James P Watt et al.   LANCET

A Randomized Trial to Determine the Tolerability and Immunogenicity of a Quadrivalent Meningococcal Glycoconjugate Vaccine in Healthy Adolescents

(2009) Lisa A. Jackson et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity of a 2-Dose Priming and Booster Vaccination With the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine

(2009) Sven Arne Silfverdal et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the Licensed 7vCRM Vaccine

(2009) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Universal childhood immunisation against Streptococcus pneumoniae: The five-year experience of Liguria Region, Italy

(2009) Paolo Durando et al.   VACCINE

Meningococcal C conjugate vaccine: The experience in England and Wales

(2009) Helen Campbell et al.   VACCINE

The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells

(2008) M. Mamani-Matsuda et al.   BLOOD

Safety profile of pneumococcal conjugate vaccines: systematic review of pre-and post-licensure data

(2008) Frank DeStefano   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Immunogenicity of a Reduced Schedule of Meningococcal Group C Conjugate Vaccine Given Concomitantly with the Prevenar and Pediacel Vaccines in Healthy Infants in the United Kingdom

(2008) J. Southern et al.   Clinical and Vaccine Immunology

Effects of Ageing and Gender on Naturally Acquired Antibodies to Pneumococcal Capsular Polysaccharides and Virulence-Associated Proteins

(2008) B. Simell et al.   Clinical and Vaccine Immunology

Risk of Guillain‐Barré Syndrome following Serogroup C Meningococcal Conjugate Vaccine in Quebec, Canada

(2008) Philippe De Wals et al.   CLINICAL INFECTIOUS DISEASES

Nasopharyngeal Carriage of Streptococcus pneumoniae in Gambian Infants: A Longitudinal Study

(2008) P. C. Hill et al.   CLINICAL INFECTIOUS DISEASES

Type I Streptococcus pneumoniae carbohydrate utilizes a nitric oxide and MHC II-dependent pathway for antigen presentation

(2008) Christopher D. Velez et al.   IMMUNOLOGY

Immunogenicity of a Tetravalent Meningococcal Glycoconjugate Vaccine in Infants

(2008) Matthew D. Snape et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Population Snapshot of EmergentStreptococcus pneumoniaeSerotype 19A in the United States, 2005

(2008) Matthew R. Moore et al.   JOURNAL OF INFECTIOUS DISEASES

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

(2008) Martin C. J. Maiden et al.   JOURNAL OF INFECTIOUS DISEASES

Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years

(2008) Lars Østergaard et al.   VACCINE

Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign

(2007) S Ladhani et al.   ARCHIVES OF DISEASE IN CHILDHOOD